Outcomes
PK/PD
SECONDARY
Primary endpoints included safety and tolerability, and change from baseline in total IgG, IgG subclasses (1–4), and anti‐AChR antibodies at 6 weeks post‐baseline. Secondary endpoints included immunogenicity (determined by percentage change from baseline in anti‐batoclimab antibodies) and characterization of any anti‐batoclimab antibodies to confirm neutralization potential at 6 weeks post‐baseline. Additional secondary endpoints included PK/PD variables and change in scores from baseline to 6 weeks post‐baseline for QMG, MG‐ADL, MGC, and MG‐QoL15r.